Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Port-Wine Stain Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Skin Imaging to Inform Laser Treatments

NCT04336163
View directory record Official record
Conditions
Port-Wine Stain, Rosacea, Telangiectasia, Angioma
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
4 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

Novel Treatment for Port Wine Stain Birthmarks

NCT01924273
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Talaporfin sodium
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 9, 2026, 12:36 AM EDT
Terminated Early Phase 1 Interventional

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

NCT01015300
View directory record Official record
Conditions
Hemangioblastomas, Von Hippel Lindau Disease
Interventions
Avastin
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 9, 2026, 12:36 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

NCT05171894
View directory record Official record
Conditions
Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Interventions
Hemopfin+Green Light, Vehicle+Green Light
Drug · Device
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser

NCT00585338
View directory record Official record
Conditions
Vascular Lesion
Interventions
Tandem 532/1064 nm Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.

NCT00800722
View directory record Official record
Conditions
Port Wine Stain
Interventions
Rapamycin Treatment of Port Wine Stain
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Not applicable Interventional Results available

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

NCT01775722
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Pulsed Dye Laser, Combined Bipolar Radiofrequency&Pulsed Dye Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hemangioma Growth During the First 6 Months of Life

NCT00911781
View directory record Official record
Conditions
Hemangiomas of Infancy
Interventions
No intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 5 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 9, 2026, 12:36 AM EDT
Withdrawn Phase 2 Interventional

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

NCT01997255
View directory record Official record
Conditions
Sturge Weber Syndrome
Interventions
Everolimus
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 9, 2026, 12:36 AM EDT
Withdrawn No phase listed Observational

Effect of Laser Treatment on Capillary Malformations

NCT02035319
View directory record Official record
Conditions
Capillary Malformation, Port Wine Stain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 9, 2026, 12:36 AM EDT
Not listed Early Phase 1 Interventional

Topical Simvastatin for Treating Infantile Hemangioma

NCT06273111
View directory record Official record
Conditions
Hemangioma Skin
Interventions
5% simvastatin ointment
Drug
Lead sponsor
Joyce Teng
Other
Eligibility
3 Months to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Measurement Skin Temperature During Pulsed Laser Exposure

NCT00540917
View directory record Official record
Conditions
Port-Wine Stain
Interventions
cooling spray during laser treatment
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
7 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab, E10030
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples

NCT02051101
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Biopsy sample from Port Wine Stain Birthmark
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Day and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths

NCT00573729
View directory record Official record
Conditions
Port Wine Stains
Interventions
Pulsed Dye Laser 577 nm, Pulsed Dye Laser 595 nm
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
6 Months and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Terminated Phase 2 Interventional Results available

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

NCT01266070
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Dovitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Not applicable Interventional Results available

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

NCT00585247
View directory record Official record
Conditions
Port Wine Stain
Interventions
Imiquimod, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

NCT00974129
View directory record Official record
Conditions
Hemangioma
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Up to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 9, 2026, 12:36 AM EDT
Recruiting Not applicable Interventional

Tolerability of 532 nm Laser Treatment of Port Wine Stains

NCT05841628
View directory record Official record
Conditions
Port-Wine Stain
Interventions
532 nm laser treatment
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 9, 2026, 12:36 AM EDT
Completed Phase 1 Interventional

Optical Clearing of the Skin in Conjunction With Laser Treatments

NCT00580736
View directory record Official record
Conditions
Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
Interventions
Optical Clearing
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 9, 2026, 12:36 AM EDT
Recruiting Phase 4 Interventional

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT04081701
View directory record Official record
Conditions
CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Interventions
Ga68-DOTATATE-PET/MRI
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 9, 2026, 12:36 AM EDT
Recruiting Not applicable Interventional

Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients

NCT07183644
View directory record Official record
Conditions
Port Wine Stains
Interventions
Pulse Dye laser, Pulse Dye Laser (PDL) pulse width stacking, Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser., IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL), Cupping followed by Pulse Dye Laser (PDL)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 12:36 AM EDT